Related Experiment Video
Updated: May 16, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
From congress to clinic: relevant trials presented at European Society of Gynaecological Oncology 2026
Letícia Vecchi Leis1, Jéssica Monteiro Vasconcellos2, Mariana Carvalho Gouveia3
1Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; Instituto D'Or de Ensino e Pesquisa (IDOR), São Paulo, Brazil.
Abstract:
"From Congress to Clinic: Relevant Trials Presented at European Society of Gynaecological Oncology (ESGO) 2026" summarizes the most clinically relevant studies presented at the 27th Congress of European Society of Gynaecological Oncology, held in Copenhagen, Denmark, from February 26 to 28, 2026. The meeting gathered more than 3000 attendees from over 100 countries and featured more than 100 international speakers, over 1200 abstracts, and more than 200 scientific lectures highlighting advances across gynecologic malignancies.Recent progress in gynecologic oncology continues to be driven by immunotherapy, targeted therapies, and biomarker-guided treatment strategies. At European Society of Gynaecological Oncology 2026, several presentations explored novel systemic therapies, innovative treatment combinations, and evolving maintenance approaches in ovarian, endometrial, cervical, and rare gynecologic cancers.This review highlights selected trials presented at the congress with the greatest potential to influence clinical practice and guide future research in gynecologic oncology.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
